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Abstract
BACKGROUND: Breast cancer tends to respond differently to treatments, which are usually determined by 
clinicopathological characteristics. Several studies evaluated the role of the peripheral blood test as diagnostic 
and prognostic markers in several types of solid cancer and neutrophil-to-lymphocyte ratio (NLR) and platelet-
tolymphocyte ratio (PLR) are two of them which already tested. However, the evidence in breast cancer is still lacking. 
AIM: Therefore, the study aimed to investigate the value of NLR and PLR as biomarkers concerning breast cancer 
stage.
METHODS: A retrospective study was conducted using breast cancer patients’ medical records from 2014 to 2019 
at Sanglah General Hospital. The histopathological records and complete blood counts of the patients were collected 
and analyzed risk analysis model, receiver operator characteristics analysis, and correlation of NLR and PLR with 
cancer staging analysis used correlation test.
RESULT: One hundred five patients data were used in this study, with 35 subjects had early-stage breast cancer 
while 70 subjects had an advanced stage. Breast cancer staging with NLR and PLR showed significant associations 
(p < 0.001). Both NLR and PLR had area under the curve >0.7 (p < 0.001). The cutoff, sensitivity, and specificity 
values of NLR and PLR were 2.504 (71%; 70%) and 157.1 (73%; 70%). Advanced stage of breast cancer was 
mostly found in high NLR and PLR value with (OR: 4.231; CI = 1.791-9.995, p < 0.001) and (OR: 3.949; 95% 
CI = 1.679–9.287; p < 0.001).
CONCLUSION: From this preliminary study, pretreatment NLR and PLR values might determine the breast cancer 
stage. Further research is needed to evaluate the association between grade and patient survival.
Edited by: Ksenija Bogoeva-Kostovska
Citation: Wiranata S, Anjani IAW, Saputra IPGS, 
Sadvika IGAS, Prabawa IPY, Supadmanaba IG, 
Wihandani DM, Adiputra PAT, Sudarsa IW, Lestari AAW. 
Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-
to-Lymphocyte Ratio as a Stage Determination in Breast 
Cancer. Open Access Maced J Med Sci. 2020 Oct 20; 
8(B):1058-1063. 
https://doi.org/10.3889/oamjms.2020.5336
Keywords: Breast cancer; Platelet lymphocyte ratio; 
Staging
 *Correspondence: Anak Agung Wiradewi Lestari, 
Department of Clinical Pathology, Faculty of Medicine, 
Udayana University, Sanglah General Hospital, Bali, 
Indonesia. 
E-mail: wiradewilestari@gmail.com.
Received: 31-Jul-2020
Revised: 04-Oct-2020
Accepted: 10-Oct-2020
Copyright: © 2020 Sinta Wiranata, Ida Ayu WidyaAnjani, 
I Putu Gede Septiawan Saputra, I Gusti Ayu Stiti Sadvika, 
I Putu Yuda Prabawa, I Gede Supadmanaba, 
Desak Made Wihandani, Putu Anda Tusta Adiputra, 
I Wayan Sudarsa, Anak Agung Wiradewi Lestari
Funding: The authors themselves supported the funding 
without the involvement of grants, research scholarships, 
or other funding sources
Competing Interest: The authors have declared that no 
competing interest exists
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
Breast cancer is the most common cancer, 
followed by cervical cancer in women. The incidence 
rate associated with breast cancer is about 11.6% of 
cancer worldwide and currently in second place after 
lung cancer. The mortality rate of breast cancer is the 
highest in women worldwide [1]. Futhermore, breast 
cancer in Indonesia has the most number of new cases 
(30.9%) in all ages among woman. It’s become the 
most prevalence cancer in both sex (16.7%) [2].
Treatment outcomes in breast cancer 
depend on several variables and clinicopathological 
characteristics are among the most substantial factors in 
determining management and survival [3], [4]. However, 
in some cases, even early-stage cancer could lead to 
severe outcomes, while advanced stage cancer could 
also progress slowly. Overall, it remains a challenge for 
the scientist to predict the outcome of breast cancer. 
Some predictive markers have been investigated, but 
molecular detection is still regarded as expensive and 
affordable in developing countries [5].
Inflammation recognizes as one of the hallmarks 
of cancer in the recent decade. Inflammation plays an 
essential role in enhancing tumor growth, angiogenesis, 
and metastasis. Localized inflammation in cancer 
tissue also extends systemically and reflects peripheral 
white blood cell composition change [5]. Recently, 
scientists put some interest in hematological markers of 
inflammation as predictive markers in cancer. Several 
studies had investigated the role of some markers such 
as platelet, lymphocyte, and monocytes in a peripheral 
blood test as a prognostic tool in cancer assessment 
[6], [7], [8]. According to the Lasorda study was found 
platelet-to-lymphocyte ratio (PLR) significant with tumor 
size (p = 0.04), meanwhile contrast with neutrophil-to-
lymphocyte ratio (NLR) (p = 0.7) [9]. These hematologic 
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markers are inexpensive and widely applicable in 
clinical practice. Among these markers, NLR and PLR 
are considered hematological markers correlated with 
unfavorable outcomes in some solid tumors such as lung 
cancer and colorectal cancer [10]. Prabawa et al. (2019) 
also showed that NLR’s median value was significantly 
higher at the advanced stage than early-stage cervical 
cancer (r = 0.638; p = 0.001) [11]. Studies by Noh et al. 
(2013) showed a direct association between NLR values 
above 2.5 with tumor size, young age (<40 years old), 
and HER2 +breast cancer [12]. A study by Prabawa et 
al. (2019) also showed a significant association between 
PLR and FIFO stage (p < 0.001) in cervical cancer 
patients [11]. A meta-analysis study reported a significant 
increase in having an advanced tumor in breast cancer 
patients with high PLR (OR = 1.86, 95% CI = 1.2–2.9) 
[13]. However, there are still limited resources about 
the link between pretreatment NLR and PLR with the 
breast cancer stage. The revelation of their association 
will strengthen the basis to validate their application in a 
clinical setting. Therefore, this study aimed to investigate 
the link between pretreatment NLR and PLR with the 
stage of breast cancer.
Patients and Methods
Patient selection and ratio calculation
In this study, after all, samples were selected 
according to the inclusion and exclusion criteria. There 
were 105 eligible samples. This study’s inclusion 
criteria were complete medical and pathological data 
for all variables and demographic data. The patients 
were diagnosed in 2014 and 2019 in Sanglah General 
Hospital, Bali, Indonesia, had not received treatment 
yet. The exclusion criteria were as follow: Patients who 
had infectious diseases, autoimmune diseases, steroid 
administration, and relapse of breast cancer that have 
gotten treatment.
After that, data input was carried out based on 
determined variables before the patients received any 
treatments and have been diagnosed with breast cancer, 
such as chronological age, clinical stages that classified 
into early-stage (I-II) and advanced stage (III-IV), parity was 
classified into nullipara, primipara, multipara, grande para, 
histopathological types as a microscopic classification, 
menarche and menopausal age after diagnosed in 
breast cancer, but has not received any treatment yet, 
grade (I-III), hematologic markers in 109/L such as white 
blood cell, neutrophil, monocyte, lymphocyte, basophil, 
eosinophil, and platelet. Furthermore, the absolute count 
of platelet, neutrophil, basophil, monocyte, and eosinophil 
each is divided with an absolute count of lymphocyte to 
produce PLR, NLR, basophil to lymphocyte ratio (BLR), 
monocyte to lymphocyte ratio (MLR), and eosinophil to 
lymphocyte ratio (ELR).
Statistical analysis
The study was analyzed using the Statistical 
Package for the Social Sciences (SPSS Inc., Chicago, 
IL, USA) version 25. The normality of continuous variable 
distribution was determined by the Kolmogorov–Smirnov 
test (KS-test). The data were reported as mean ± standard 
deviation, ratio, 95% IC, cutoff value, sensitivity, and 
specificity. The associations between stage with NLR, 
PLR, MLR, BLR, and ELR were assessed using the 
Mann–Whitney test. Categorical data were analyzed by 
chi-square. The cutoff point for the ratio was determined 
using the receiver operating characteristic (ROC) curve 
by considering the value of sensitivity and specificity. p ≤ 
0.005 is considered as statistically significant.
Results
Subject characteristics
Regarding the subjects’ age, both groups 
have comparable mean age (advance stage group: 
50.82 ± 11.274 years-old; early-stage group: 52.30 
± 10.364 years-old). Surprisingly, there was also no 
significant difference between both groups in terms of 
histopathological characteristics. However, variability 
was observed when comparing the hematological 
parameters in which both groups differ significantly in 
neutrophil, lymphocyte, and platelet counts. As predicted, 
the NLR and PLR were also significantly different. 
Table 1 summarizes the subjects’ demographical, 
pathological, and hematological characteristics and 
compares early and late-stage groups.
Table 1: Breast cancer characteristic, histopathological 
features, and blood parameters
Characteristic Early (n = 35) Advanced (n = 70) p
Age (years) 52.30 ± 10.364 50.82 ± 11.274 0.71
Menarche (years) 10.44 ± 6.318 9.43 ± 6.77 0.25
Menopause (years) 22.03 ± 24.47 16.50 ± 23.11 0.67
Parity (n, %) 0.26
Nullipara 10 (9.5%) 25 (23.8%)
Primipara 3 (2.9%) 3 (2.9%)
Multipara 19 (18.1%) 41 (39%)
Grande para 3 (2.9%) 1 (1%)
Grade (n, %) 0.36
1 3 (2.9%) 4 (3.8%)
2 21 (20%) 22 (21%)
3 19 (18.1%) 36 (34.3%)
Histopathology (n, %) 0.97
Invasive carcinoma of no special type 39 (37.1%) 57 (54.3%)
Invasive lobular carcinoma 2 (1.9%) 2 (1.9%)
Non-invasive carcinoma 1 1%) 1 (1%)
Special type carcinoma 1 (1%) 2 (1.9%)
Blood parameters
White blood cell (109/L) 7.35 ± 1.896 6.71 ± 3.228 0.09
Neutrophil (109/L) 4.06 ± 1.875 3.98 ± 2.195 0.04*
Monocyte (109/L) 0.51 ± 0.135 0.49 ± 1.999 0.6
Lymphocyte (109/L) 1.52 ± 1.144 1.94 ± 1.238 0.02*
Basophils (109/L) 0.06 ± 0.043 0.07 ± 0.035 0.63
Eosinophil (109/L) 0.18 ± 0.073 0.22 ± 0.273 0.19
Platelet (109/L) 101.92 ± 1.687 247.92 ± 3.873 0.04*
NLR 1.62 ± 0.779 2.46 ± 1.756 0.003*
PLR 115.94 ± 3.799 169.91 ± 2.930 0.002*
MLR 0.20 ± 0.051 0.32 ± 0.202 0.07
BLR 0.02 ± 0.017 0.046 ± 0.022 0.34
ELR 0.07 ± 0.030 0.11 ± 0.085 0.10
*Statistically significant (p < 0.05); SD: Standard deviations, NLR: Neutrophil-to-lymphocyte ratio, 
PLR: Platelet-to-lymphocyte ratio, MLR: Monocyte-to-lymphocyte ratio, BLR: Basophil-to-lymphocyte ratio, 
ELR: Eosinophil-to-lymphocyte ratio.
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ROC curve of sensitivity and specificity of 
NLR, PLR, MLR, BLR, and ELR as hematological 
markers in the breast cancer stadium
A ROC analysis performed the NLR, PLR, 
MLR, BLR, and ELR predictive value and identified 
their diagnostic values (sensitivity and specificity). 
According to the ROC curve, NLR and PLR emerged 
as potential markers since their area under the curve 
(AUC) value was >0.70, which indicated an excellent 
predictive parameter. The cutoff point of each ratio was 
also identified through ROC analysis, and it was shown 
that NLR had 71% sensitivity, 70% specificity, with a 
cutoff value of 2.504 while PLR had 73% sensitivity, 
70% specificity, and a cutoff value of 157.1. Table 2 
presents the detail of ROC analysis. 
Table 2: Advanced stage of AUC, cutoff value, sensitivity, and 
specificity for NLR, PLR, MLR, BLR, and ELR in breast cancer 
patients
Stage Parameter AUC 95% CI Cutoff 
value
Sensitivity 
(%)
Specificity 
(%)
p
Advanced NLR 0.733 0.632 – 0.833 2.504 71 70 <0.001*
PLR 0.735 0.636 – 0.833 157.1 73 70 <0.001*
MLR 0.681 0.575 – 0.788 0.246 67 60 0.003*
BLR 0.681 0.578 – 0.784 0.042 59 57 0.003*
ELR 0.625 0.520 – 0.730 0.093 60 60 0.037*
*Statistically significant (p < 0.05); NLR: Neutrophil-to-lymphocyte ratio, PLR: Platelet-to-lymphocyte ratio, 
MLR: Monocyte-to-lymphocyte ratio, BLR: Basophil-to-lymphocyte ratio, ELR: Eosinophil-to-lymphocyte ratio, 
AUC: Area under the curve, CI: Confidence interval.
Risk analysis model of hematological 
markers as a predictive value in the advance stage 
of breast cancer
Using the cutoff value from ROC analysis, a 
two-step risk analysis was performed using cross-
tabulation to assess each variable, odds ratio (OR), 
and logistic regression to identify the adjusted OR 
(Figure 1). Bivariate risk analysis showed that NLR, 
PLR, and MLR significantly associated with a higher 
risk of having advanced tumor stadium, with NLR, 
possessed the highest OR value (OR: 4.231; 95%CI: 
1.791-9.995; p = 0.001). However, multivariate 
regression analysis showed that only NLR and PLR 
could predict advanced tumor stadium while MLR was 
proved to be not significant (Table 3).
Discussion
In this study, we strengthen the findings from 
the previous study, and we also compared four different 
ratios instead of focusing on one. Our study found that 
there were already significant differences in neutrophil, 
lymphocyte, and platelet between patients with early-
stage compared to an advanced stage even from the 
absolute counts. The values tended to be higher in 
the advanced stage than in the early stage, except for 
neutrophil count. Thus, the NLR and PLR were also 
significantly different between the two groups.
These findings are in line with several other 
studies that also assess the diagnostic or predictive 
value of lymphocyte ratios. For example, Elyasinia 
et al. (2017) found a significant relationship between 
neutrophil and platelet with breast cancer staging [14]. 
Theoretically, the number of lymphocytes is correlated 
with tumor stage because of its inherent nature as 
a cellular-based immune response in eliminating 
cancer [15]. However, a higher number is not always 
associated with the greater immune response since 
cancer cells can modulate the immune response through 
immune-tolerance cytokines production of tumor micro 
environment. As for platelet, its higher count is often 
associated with a higher tumor cell migration rate as it 
protects circulating tumor cells and provides necessary 
growth factors needed when tumor cells arrived in the 
target organ [16]. Therefore, a higher ratio of platelet 
lymphocytes can be considered an indicator of tumor 
progression, especially in vascular invasion proven in 
breast cancer [14].
Some previous studies also showed a 
significant relationship between NLR and PLR with 
the stage of several types of cancer. Studies by Noh 
et al. (2013) conducted a direct association between 
NLR values above 2.5 with tumor size, young age 
(<40 years old), and HER2 + breast cancer [12]. In 
addition, Prabawa et al. (2019) also showed that NLR’s 
median value was significantly higher at the advanced 
stage than early-stage cervical cancer (r = 0.638; 
p = 0.001) [11]. This association was also confirmed in 
a meta-analysis by Huang et al. (2017), which found a 
significant association between NLR with tumor stadium 
in esophageal squamous cell carcinoma patients [17]. 
However, Aslan et al. (2016) found no significant 
relationship between NLR with the clinicopathological 
aspects of follicular lymphoma, but the lymphoma’s 
Figure 1: Receiver operating characteristic analysis of neutrophil-
to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), 
monocyte-to-lymphocyte ratio, basophil-to-lymphocyte ratio, and 
eosinophil-to-lymphocyte ratio as predictive values in the advanced 
stage of breast cancer. The diagonal reference line is an indicator of 
no diagnostic value. Among those ratios, NLR and PLR were the only 
variables that had area under the curve value > 0.70.
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hematological nature might cause this finding [18]. 
Therefore, NLR can still be considered as one of the 
potential hematological biomarkers of concrete cancer. 
The Explanation of neutrophil pathological role by 
looking into a histologic tumor sample where neutrophil 
is often present at the tumor rim as tumor-associated 
neutrophils (TAN) can release pro-tumorigenic 
molecules that support angiogenesis, invasion, and 
migration of cancer cells [17].
On the other hand, PLR also has been shown 
to significantly associate with tumor stadiums, as 
reported by Yersal et al. [19]. In addition, Prabawa et al. 
(2019) also showed a significant association between 
PLR and FIFO stage (p < 0.001) in cervical cancer 
patients [11]. A study by Krenn-Pilko et al. (2014) and 
Graziano et al. (2019) showed that high PLR value 
was related to larger tumor size [20], [21]. A meta-
analysis study reported a significant increase in having 
an advanced tumor in breast cancer patients with high 
PLR (OR = 1.86, 95% CI = 1.2 – 2.9) [13]. However, 
Zhu et al. (2017) reported no relationship between PLR 
with breast cancer stadium [10]. Therefore, there are 
still some un-resolving issues regarding the role of PLR 
as a diagnostic or predictive marker in breast cancer. 
However, pathologically, platelets support tumor 
progression by shielding tumor cells from natural killer 
cells and producing angiogenic and growth factors, 
including vascular endothelial growth and platelet-
derived growth factors [22], [23], [24], [25].
Regarding the diagnostic value, our study 
showed that NLR and PLR had the highest level 
of sensitivity and specificity, among other variables 
at a specific cutoff point. In line with this study, a 
systematic review and meta-analysis by Ethier et al. 
(2017) reported that NLR predicted overall survival and 
disease-free survival of breast cancer patients with a 
cutoff value of 1.9–5.0 (median cutoff value 3.0)  [26] 
findings. Ulas et al. (2015) obtained significant results 
at a cutoff value of 161 [27]. Furthermore, Yao et al. 
(2014) obtained significant results at a cutoff value of 
107 [28]. Separately, Cihan et al. (2014) found similar 
findings using a cutoff value at 1.60, which was linear 
with Ulas et al. and Yao et al. [28] that research shows 
that the NLR and PLR are promising and potential 
biomarkers in breast cancer, but the cutoff values need 
to be validated [27], [28], [29]. Additional evidence by 
Orditura et al. (2016) showed a further role of NLR as a 
predictive marker of distant metastasis-free survival of 
a breast cancer patient [30].
Aside from predicting tumor stadium, PLR and 
NLR are also associated with breast cancer patient’s 
mortality rates. Patients with an NLR >5.64 only had 
a 5-year survival rate at 51.1%, while patients with 
PLR >215 had a 5-year survival rate at 53.2% [15]. 
Gynecologic evidence also revealed that baseline 
values of NLR ≥4.1 and PLR ≥0.3 were associated with 
a higher risk of metastases compared to patients with 
below cutoff point NLR and PLR [31]. Other than these, 
NLR and PLR were also associated with tumor stadium 
and metastasis in osteosarcoma and chemosensitivity 
in gastric cancer [32], [33], [34].
However, this study has several limitations, 
which are essential to be considered in generalizing the 
findings. First, this study used a retrospective cohort 
design, which is prone to bias. Selective sample selection 
we used to reduce the bias according to inclusion and 
exclusion criteria. In addition, hematological markers are 
susceptible to a patient’s condition and are affected by 
several factors, including nutrition and bone metastasis. 
Nevertheless, hematologic biomarkers have several 
advantages worth considering, such as affordable and 
applicable, which can benefit oncologists in developing 
countries.
Conclusion
PLR and NLR are the potential to determine 
cancer staging in breast cancer. However, a further 
study is needed to assess the optimal cutoff point and 
its associated factors as well as a further study involving 
recurrence rate and chemoresistance.
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NLR 4.231 (1.791 – 9.995) 0.001* 3.024 (1.207 – 7.580) 0.018*
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Low 22 (21.0) 20 (19.0)
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